文献速递垂体与肾上腺疾病

转移性嗜铬细胞瘤和副神经节瘤的系统治疗进展

Approach to the patient with metastatic pheochromocytoma and paraganglioma: advances in systemic therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述转移性嗜铬细胞瘤和副神经节瘤(MPPGL)的系统治疗格局演变,指出约25%的PPGL发生转移,且所有PPGL均被视为具有转移潜能;除环磷酰胺、长春新碱和达卡巴嗪化疗外,多种靶向放射性药物、多靶点酪氨酸激酶抑制剂(舒尼替尼、卡博替尼)及HIF-2α抑制剂贝组替凡已显示疾病控制作用,贝组替凡成为FDA首个获批的口服疗法。文章提出整合临床表型和肿瘤基因型的治疗算法,并强调多学科管理的重要性。

要点

  • 约25%的PPGL发生转移,所有PPGL均需视为具有转移潜能。
  • 贝组替凡成为FDA首个获批用于MPPGL的口服HIF-2α抑制剂。
  • 舒尼替尼和卡博替尼在 prospective 临床试验中显示显著疾病控制。

核心结论

  • MPPGL系统治疗选择显著扩展,贝组替凡为首个FDA获批口服疗法,多学科管理至关重要。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • 约25%的PPGL发生转移(MPPGL),导致显著疾病负担和高儿茶酚胺血症相关并发症。
  • MPPGL生物学行为异质,部分侵袭性强需强化治疗,部分惰性多年无需治疗。
  • 环磷酰胺、长春新碱和达卡巴嗪化疗之外,多种靶向放射性药物对MPPGL显示活性。
  • 舒尼替尼和卡博替尼在前瞻性临床试验中显示对MPPGL的显著疾病控制。
  • 贝组替凡显示持久缓解、高血压改善和生活质量维持,成为FDA首个获批口服疗法。

关键数值与推荐

  • 所有PPGL均被视为具有转移潜能,因缺乏足够准确的未来行为预测因子。

临床怎么用

  • 整合临床表型和肿瘤基因型的算法可指导个体化系统治疗选择。
  • 多学科管理应作为MPPGL治疗的核心组成部分。

局限性

  • 为综述性文章,未报告原始研究的具体样本量、置信区间或P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pheochromocytomas and paragangliomas (PPGLs) are rare tumors of the adrenal and extra-adrenal chromaffin cells. Although most PPGLs remain localized, approximately 25% develop metastatic disease (MPPGL), leading to substantial morbidity due to tumor burden and catecholamine excess. These tumors have a heterogeneous biologic activity, with some having an aggressive course requiring intensive treatment, and others behaving indolently, not requiring treatment over many years. Because there are no sufficiently accurate predictors of future behavior, all PPGLs are considered to have the potential for metastatic disease. Over the past decade, the treatment landscape for MPPGL has evolved dramatically. In addition to cytotoxic chemotherapy with cyclophosphamide, vincristine, and dacarbazine, several targeted radiopharmaceuticals have shown activity against MPPGL. Furthermore, multi-target tyrosine kinase inhibitors, including sunitinib and cabozantinib, have demonstrated substantial disease control in prospective clinical trials. Most notably, belzutifan, a hypoxia-inducible factor-2α inhibitor, recently became the first oral therapy approved by the US Food and Drug Administration for MPPGL, demonstrating durable responses, improvement in hypertension, and preservation of quality of life. In this review, we highlight an illustrative case of MPPGL and provide a contemporary framework of the treatment landscape. We also present an algorithm that integrates clinical phenotype and tumor genotype to advise which systemic therapies may benefit individual patients with MPPGL. As therapeutic options continue to expand, we emphasize the role of multidisciplinary management as essential in the treatment of these rare and biologically complex malignancies.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Glover M, Waguespack SG, Campbell MT, et al. Approach to the patient with metastatic pheochromocytoma and paraganglioma: advances in systemic therapy. J Clin Endocrinol Metab. 2026. PMID: 42025325. doi:10.1210/clinem/dgag182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。